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Abstract
Background: Interleukin-33 (IL-33) is an IL-1-like cytokine ligand for the IL-1 receptor-related protein ST2, that activates mast
cells and Th2 lymphocytes, and induces production of Th2-associated cytokines in vivo. We initially discovered IL-33 as a
nuclear factor (NF-HEV) abundantly expressed in high endothelial venules from lymphoid organs, that associates with
chromatin and exhibits transcriptional regulatory properties. This suggested that, similarly to IL-1a and chromatin-
associated cytokine HMGB1, IL-33 may act as both a cytokine and a nuclear factor. Although the activity of recombinant IL-
33 has been well characterized, little is known yet about the expression pattern of endogenous IL-33 in vivo.
Methodology/Principal Findings: Here, we show that IL-33 is constitutively and abundantly expressed in normal human
tissues. Using a combination of human tissue microarrays and IL-33 monoclonal and polyclonal antibodies, we found that IL-
33 is a novel nuclear marker of the endothelium widely expressed along the vascular tree. We observed abundant nuclear
expression of IL-33 in endothelial cells from both large and small blood vessels in most normal human tissues, as well as in
human tumors. In addition to endothelium, we also found constitutive nuclear expression of IL-33 in fibroblastic reticular
cells of lymphoid tissues, and epithelial cells of tissues exposed to the environment, including skin keratinocytes and
epithelial cells of the stomach, tonsillar crypts and salivary glands.
Conclusions/Significance: Together, our results indicate that, unlike inducible cytokines, IL-33 is constitutively expressed in
normal human tissues. In addition, they reveal that endothelial cells and epithelial cells constitute major sources of IL-33 in
vivo. Based on these findings, we speculate that IL-33 may function, similarly to the prototype ‘alarmin’ HMGB1, as an
endogenous ‘danger’ signal to alert the immune system after endothelial or epithelial cell damage during trauma or
infection.
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Introduction
IL-33 (initially designated NF-HEV for ‘‘Nuclear Factor from
High Endothelial Venules’’ [1]) is the most recent addition to the
IL-1 family [2,3]. It has been shown to function as a ligand for the
IL-1 receptor-related protein ST2 (IL-1R4), a receptor expressed
on mast cells, T helper type 2 (Th2) lymphocytes and
cardiomyocytes [2,4]. Accordingly, recombinant IL-33 was found
to drive production of pro-inflammatory and Th2-associated
cytokines in mast cells and Th2 lymphocytes [2,5–10], to induce
chemotaxis of Th2 cells [11] and to protect the heart against
cardiac stress [4] and atherosclerosis [12]. The effects of IL-33
were found to be abrogated in the absence of the IL-1R accessory
protein (IL-1RAcP), a signaling receptor subunit that is also a
member of the IL-1R complex, indicating that ST2/IL-1RAcP
comprise the IL-33 signaling receptor complex [7,13].
Although the functional properties of recombinant IL-33 have
been well characterized, little is known yet about endogenous IL-
33 in vivo. Using in situ hybridization and immunohistochemistry
with three distinct antisera, we previously reported that IL-33 is
abundantly expressed in endothelial cells of high endothelial
venules (HEVs), specialized blood vessels which mediate lympho-
cyte recruitment into lymphoid organs [1,3]. We showed that IL-
33 possesses transcriptional regulatory properties and associates
with chromatin in the nucleus of HEV endothelial cells in vivo
[3,14]. Together, these observations suggested that IL-33 is a dual
function protein that may act as both a cytokine and an
intracellular nuclear factor [3,14,15]. A similar duality of function
has previously been shown for IL-1a and chromatin-associated
cytokine HMGB1. IL-1a, a cell-associated cytokine, exhibits
potent pro-inflammatory cytokine activities mediated by the cell
surface IL-1 receptors [16] but also functions intracellularly, by
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HMGB1 regulates transcription, chromatin structure and function
in the nucleus [18] but also functions as a potent proinflammatory
cytokine when released after tissue injury and cell necrosis [19–21]
or actively secreted by macrophages during inflammation [22]. IL-
1a and HMGB1 were thus defined as endogenous ‘danger’ signals
or ‘alarmins’ that may alert the immune system after cell and tissue
damage during trauma or infection [23].
So far, HEV endothelial cells constitute the only human cell
type that has been shown to express endogenous IL-33 at both the
mRNA and protein level in vivo. In situ hybridization studies also
indicated that endothelial cells constitute a major source of IL-33
in chronically inflamed tissues from patients with rheumatoid
arthritis and Crohn’s disease [3]. In contrast to these in vivo
analyses, real-time quantitative PCR (qPCR) studies in cultured
cells revealed expression of IL-33 mRNA in arterial smooth
muscle cells, bronchial epithelial cells and activated dermal
fibroblasts and keratinocytes, but expression in endothelial cells
was not reported [2]. Recently, studies in rodents indicated that
IL-33 is expressed in the heart, by cardiac fibroblasts after
mechanical stress [4] and by endothelial cells during atheroscle-
rosis [12].
In the present study, we used a combination of human tissue
microarrays, IL-33 monoclonal and polyclonal antibodies and
blocking peptides, to analyze the expression pattern of IL-33 in
vivo. We found that IL-33 is abundantly expressed in the nucleus of
endothelial cells in most normal human tissues as well as in human
tumors. In addition to the endothelium, high levels of nuclear IL-
33 were also found in fibroblastic reticular cells (FRCs) of
lymphoid tissues and certain types of epithelium, including skin
keratinocytes and epithelial cells of the stomach. Based on these
observations, we speculate that, similarly to HMGB1, IL-33 may
function as an ‘alarmin’ belonging to the larger family of damage-
associated molecular pattern (DAMP) molecules [23].
Methods
Tissue microarrays
Two different sources of human tissue microarrays were used in
this study. High density normal tissue microarray slides containing
45 normal human tissues in duplicate (AccuMax Array #
A103VI-Normal tissues) were purchased from ISU-ABXIS
(Accurate Chemical Corp, Westbury, NY, USA). Normal tissue
microarray slides that contain 31 different human tissues (Normal
adult tissue I, # 401 1110) and tumor tissue microarray slides that
contain 10 different human tumor tissues (Multitumor-10 organs
# 401 2402) were purchased from Provitro-GmbH (Berlin,
Germany). All slides were prepared with formaldehyde fixed,
paraffin-embedded human tissues cut at 5 mm.
Antibodies
IL-33 mAb (1/200, clone Nessy-1) and polyclonal antibodies (1/
200, Cter1 and Cter2, nos 210-447 and 210-933) were obtained
from Alexis Biochemicals. Rabbit polyclonal antibodies against
CD31 (1/100, Abcam), vWF (1/100, Dako) and desmin (1/75,
Abcam), rabbit mAb anti-CD3 (1/100, clone SP7, Abcam), rat
IgM mAb MECA-79 (1/200, Pharmingen), and mouse mAbs
against alpha smooth-muscle cell actin (1/100, clone 1A4, Dako),
fascin (1/100, clone 55K2, Dako) and CD68 (1/200, clone PG-
M1, Dako), were used as primary antibodies in double staining
experiments. Goat polyclonal antibodies anti-rabbit (1/200, Cy3,
Amersham; Alexa 488, Molecular Probes) or anti-mouse (1/200,
Cy3 or Cy2, Amersham; Biotin, Vector Laboratories) were used as
secondary reagents.
Immunohistochemistry and immunofluorescence
staining
5 mm paraffin sections were deparaffinized in Histo-clear
(National Diagnostics, MERCK Eurolab s.a) and rehydrated in
graded alcohol series. For staining revealed through peroxydase
activity, endogenous peroxydase was inhibited using 0.03% H2O2
in Methanol, 30 mn. The sections were then washed in distilled
water and boiled in a microwave oven for epitope retrieval in
Sodium Citrate buffer (10 mM pH 6, 20 mn). Slides were
equilibrated in PBS and incubated with blocking solution (PBS,
Goat serum 5%, BSA 5%) 1 h at room temperature. When
biotinylated secondary antibody was used, endogenous biotin was
inhibited using an avidin/biotin blocking kit from Vector. Primary
antibodieswerediluted inPBS, BSA1%andincubated overnightat
4uC. For immunofluorescence detection, the sections were washed
in PBS for 30 mn and incubated with secondary antibodies coupled
to Cy3 or Cy5 diluted in PBS, BSA 1%, 1 h at room temperature.
The sections were then washed in PBS for 30 mn and counter-
stainedwithDapiandmounted inMowiolembedding medium.For
immunoperoxydase detection, the sections were washed in PBS for
30 mn and incubated with biotinylated secondary antibodies
diluted in PBS, BSA 1%, 1 h at room temperature. The sections
were then washed in PBS for 30 mn and incubated with
Streptavidin peroxydase (Dako) diluted 1/100 in PBS, BSA 1%
for 45 mn at room temperature. Peroxydase activity was revealed
using DAB substrate (Sigma), slides were counterstained with
Methyl Green (Sigma) or Hematoxylin (Sigma), then dehydrated
and mounted in Safemount embedding medium (Labonord,
France). For peptide-blocking experiments, the IL-33 mAb and
polyclonal antibodies were adsorbed with control or IL-33 peptide
(no 522-098, Alexis Biochemicals) for 1 h at 37uC.
Image acquisition and processing
Fluorescent images were visualized using an inverted micro-
scope Eclipse TE300 Nikon with 40X/0.75 and 100X/0.5–1.3
objectives at room temperature and captured through a DXM
1200 digital camera using Nikon ACT1 software. Brightfield
images were visualized using an Eclipse 80i Nikon microscope
with 40X/0.75 and 100X/1.30 objectives at room temperature
and captured through a Digital Sight DS 5 M L1 Nikon camera
using DS 5 M L1 Nikon software. All images were processed using
Adobe Photoshop CS2 software.
Results
IL-33 is constitutively expressed in both HEVs and FRCs
networks from human secondary lymphoid tissues
A mouse mAb against human IL-33 (mouse IgG1, clone Nessy),
suitable for immunohistochemical staining, recently became
available. Immunohistochemical and immunofluorescence stain-
ing of human tonsil sections with this mAb confirmed the
abundant expression of IL-33 in the nucleus of HEV endothelial
cells (Figure 1, A and B), as expected [3]. Interestingly, nuclear
staining of scattered single cells in the interfollicular T cell areas
was also observed. This staining was specific since, it was also
observed with the anti-IL-33 rabbit polyclonal antibodies Cter1
and Cter2 (Figure 1, C and D) and it was abrogated by pre-
incubating the IL-33 mAb and polyclonal antibodies with
recombinant IL-33 peptide (Figure 1, E and F). Moreover,
staining of HEV blood vessels and isolated cells in the
interfollicular T-cell areas was also observed in other secondary
lymphoid tissues, such as lymph nodes (Figure 1G) and appendix
(Figure 1H). Interestingly, the localization of IL-33 in the nuclei of
the isolated cells was not homogenous and, similarly to HEVs,
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domains that contained high local concentrations of DNA
(Figure 1, I and J).
In an effort to identify the isolated cells in the T cell areas, we
then performed double staining of human tonsil sections with IL-
33 mAb or polyclonal antibodies, and antibodies against T cells
(CD3, Figure 2, A and B), dendritic cells (fascin, Figure 2C) or
macrophages (CD68, data not shown). However, we did not
observe colocalization of IL-33 with any of these markers. We next
examined the possibility that these cells may correspond to stromal
cells. Strikingly, double staining with an antibody against desmin,
a marker of FRCs [24,25], revealed accumulation of IL-33 in the
nucleus of desmin
+ FRCs (Figure 2, D–F). This was confirmed
using an antibody against a2smooth muscle actin (a2SMA), a
marker of myofibroblasts and FRCs [24] (Figure 2, G–I). It is
important to note, however, that the desmin
+ FRCs and the
a2SMA
+ FRCs did not always overlap, and IL-33 accumulated in
the nucleus of many, but not all, FRCs from human tonsils. We
concluded from these studies that IL-33 is a chromatin-associated
nuclear factor constitutively expressed in HEVs and FRCs from
human secondary lymphoid tissues.
IL-33 is a nuclear marker of the endothelium with
widespread expression along the vascular tree
To determine the expression profile and potential cellular
sources of IL-33 in non-lymphoid tissues, we stained human tissues
microarrays (.50 human tissues) with IL-33 antibodies. We used
two independent sources of tissue arrays to obtain a bona fide
expression profile independent of the individuals analyzed and the
Figure 1. IL-33 is a chromatin-associated nuclear factor
constitutively expressed in human secondary lymphoid tissues
by HEVs and isolated cells in the interfollicular T cells areas. A:
Immunohistochemical staining of a human tonsil section with IL-33
mAb Nessy-1. B–D: Double staining of human tonsils sections with
HEV-specific mAb MECA79 (green) and IL-33 mAb Nessy-1 (B, red) or
two distinct IL-33 polyclonal antisera, Cter1 (C, red) or Cter2 (D, red).
The follicles (fol) are indicated. E and F: Nuclear staining of HEVs and
isolated cells in the T cell areas was abrogated by pre-incubating the IL-
33 monoclonal (E) and polyclonal (F) antibodies with IL-33 peptides but
not control peptides. G and H: Nuclear accumulation of IL-33 in HEV
blood vessels and isolated cells was also observed in lymph node (G, IL-
33 mAb, red; CD31, green) and appendix (H, IL-33 mAb, red; vWF,
green). I and J: Higher magnification of a human tonsil section double-
stained with IL-33 and MECA-79 antibodies and counterstained with the
DNA-binding dye DAPI. In the nucleus of both HEVs (arrow, upper
panel) and isolated cells (arrowhead, lower panel), IL-33 accumulates in
nuclear domains that colocalize with dense regions of DAPI staining (J),
indicating association with chromatin. Magnification bars: A, I 10 mm; B,
G, H 20 mm; J 5 mm; C, D, E, F 60 mm.
doi:10.1371/journal.pone.0003331.g001
Figure 2. IL-33 is a nuclear marker of FRCs in the interfollicular
T cells areas. A and B: Double staining of human tonsils sections with
IL-33 mAb Nessy-1 (red) and anti-CD3 polyclonal antibody (green). C:
Double staining of a human tonsil section with IL-33 polyclonal
antibody Cter2 (green) and anti-fascin mAb (red). D–F: Double staining
of a human tonsil section with IL-33 mAb Nessy-1 (red) and anti-desmin
polyclonal antibody (green). A follicle is indicated (fol). Higher
magnification (E) and DAPI counterstaining (F) are shown to reveal
nuclear accumulation of IL-33 in desmin
+ cells. G–I: Double staining of a
human tonsil section with IL-33 polyclonal antibody Cter2 (green) and
anti-a-SMA mAb (red). a-SMA is detected in the basal lamina of an HEV
blood vessel (G) but is not expressed by the HEV endothelial cells.
Higher magnification (H) and DAPI counterstaining (I) reveals nuclear
accumulation of IL-33 in a-SMA
+ cells. Magnification bars: A, D 60 mm; B,
C, G 25 mm; E, F, H, I 10 mm.
doi:10.1371/journal.pone.0003331.g002
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this analysis revealed constitutive and widespread expression of IL-
33 in the endothelium from normal human tissues (Figure 3).
Specific accumulation of IL-33 in the nucleus of endothelial cells
from large blood vessels was found in most tissues, as revealed by
double staining with antibodies against endothelial cell markers
CD31 or von willebrand factor (vWF). Similarly to the staining of
HEVs and FRCs in lymphoid tissues, staining of endothelial cells
nuclei with IL-33 antibodies in non-lymphoid tissues was specific
since it was observed with both IL-33 mAb and polyclonal
antibodies, and it was abrogated by pre-incubating the antibodies
with recombinant IL-33 (data not shown). In contrast to the
endothelial cells that constitutively expressed high levels of IL-33
protein, vascular smooth muscle cells from arterial blood vessels
did not express IL-33 in vivo (Figure 3, arrowheads), despite the fact
IL-33 mRNA expression has previously been detected in arterial
SMCs in culture [2]. In the microvasculature of many tissues,
including liver, skeletal muscle, kidney (peritubular capillaries),
prostate and skin, expression of IL-33 was observed in the nucleus
of endothelial cells from small blood vessels (Figure 4). However,
some heterogeneity was found since IL-33 was not detected in the
microcirculation of the brain and kidney glomeruli (data not
shown). Together, these results indicated that IL-33 is a novel
nuclear marker of the endothelium with widespread expression
along the vascular tree.
Figure 3. IL-33 is constitutively expressed in the nucleus of
endothelial cells from large blood vessels in normal human
tissues. Expression of IL-33 in human tissues was analyzed using both
immunohistochemistry (lefts panels) and immunofluorescence staining
(right panels). Double staining was performed with IL-33 mAb Nessy-1
(red) and anti-CD31 or anti-vWF polyclonal antibodies (green). DNA was
counter-stained with DAPI. Arrowheads label the nuclei of smooth
muscle cells in arterioles that are not stained with IL-33 antibodies.
Magnification bars: 35 mm.
doi:10.1371/journal.pone.0003331.g003
Figure 4. IL-33 is constitutively expressed in the nucleus of
endothelial cells from small blood vessels in normal human
tissues. Expression of IL-33 in the microvasculature was analyzed using
immunofluorescence staining. Double staining was performed with IL-
33 mAb Nessy-1 (red) and anti-CD31 or anti-vWF polyclonal antibodies
(green). DNA was counter-stained with DAPI. Magnification bars: 20 mm.
doi:10.1371/journal.pone.0003331.g004
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endothelial cells in multiple human tumor tissues
We then asked whether IL-33 is expressed in blood vessels from
human tumor tissues. For that purpose, we double-stained human
multi-tumor tissue microarrays with antibodies against IL-33 and
CD31 or vWF (Figure 5). We found abundant expression of IL-33
in the nucleus of CD31
+ or vWF
+ endothelial cells from blood
vessels in adenocarcinomas of the kidney (Figure 5A and B),
stomach (Figure 5C and D), liver (Figure 5E and F), pancreas
(Figure 5G and H), lung, breast or colon (data not shown).
Therefore, IL-33 appeared to be a general nuclear marker of the
endothelium expressed in both normal and tumor tissues.
IL-33 is constitutively expressed in the nucleus of
epithelial cells in tissues exposed to the environment
In many tissues, IL-33 expression appeared to be restricted to
endothelial cells. However, in certain tissues exposed to the
environment, high levels of IL-33 were also found in the nucleus of
epithelial cells. For instance, IL-33 expression was detected in skin
keratinocytes (Figure 6, A–C), in epithelial cells of the mucosal
surface (Figure 6, D–F) and gastric glands (Figure 6, G and H) in
the stomach, as well as in epithelial cells of tonsillar crypts (data
not shown) and salivary glands (Figure 6I). Although IL-33
staining in skin keratinocytes and epithelial cells of the stomach
was consistently observed in all samples analyzed, significant
variability was noted between different cells, between different
parts of the tissues and between different individuals, suggesting
modulation of IL-33 expression by local environmental cues.
As discussed above, IL-33 was not constitutively expressed in
vascular smooth muscle cells in vivo (Figure 3). It was also not found
in the nucleus of cardiac or skeletal muscle myocytes. However,
nuclear expression of IL-33 was observed in visceral smooth
muscle cells of the gastrointestinal and urogenital tracts, although
it was less intense than in endothelial or epithelial cells (data not
shown). Similarly, with the exception of FRCs in lymphoid tissues,
expression of IL-33 was generally not detected in fibroblasts from
normal human tissues. For instance, IL-33 was not observed in
skin fibroblasts in vivo, despite the presence of IL-33 mRNA in
activated dermal fibroblasts in culture [2].
Discussion
Although the capacity of IL-33 to activate the ST2 receptor
expressed on Th2 cells and mast cells has been well established
[2,5–11], very little is known yet about the cellular sources of IL-33
in vivo. In the present work, using human tissue microarrays and
IL-33 monoclonal and polyclonal antibodies, we demonstrate that
IL-33 is constitutively expressed in the nucleus of endothelial cells
from both large and small blood vessels in most tissues analyzed
(.50 human tissues). These observations, which extend our
previous data that revealed expression of IL-33 in endothelial cells
from lymphoid tissues, chronically inflamed rheumatoid arthritis
synovium and Crohn’s disease intestine [1,3], demonstrate that IL-
33 is a novel nuclear marker of the endothelium in both normal
and chronically inflamed human tissues. Moreover, abundant
expression of IL-33 was also observed in the nucleus of endothelial
cells in several distinct human tumors, indicating that IL-33 is a
marker of tumor blood vessels as well. Together, these findings
provide further support to the possibility that IL-33 may play
important roles as a chromatin-associated factor in the nucleus of
endothelial cells in vivo [1,3].
In addition to endothelium, we detected abundant expression of
IL-33 in the nucleus of epithelial cells of tissues in contact with the
environment, including the skin and gastrointestinal tract, where
pathogens, allergens and other environmental agents are fre-
quently encountered. Interestingly, constitutive expression in skin
keratinocytes has previously been reported for other members of
the IL-1 family, including IL-1a and IL-1b [16,26,27]. The
constitutive expression of IL-33 in epithelial barriers of our body
thus supports the possibility that, similarly to the IL-1s, it may play
important roles in the response to injury or infection.
In all endothelial cells and epithelial cells that expressed IL-33 in
vivo, the protein accumulated in the nucleus and we found no
evidence for cytoplasmic, membrane or extracellular localization.
Therefore, it is not yet clear how IL-33 may be released from the
nucleus to exert its cytokine activities towards target cells
expressing the ST2 receptor. The mature form of IL-33 has been
proposed to be secreted after maturation by caspase-1 [2], but the
predicted cleavage site for caspase-1 is not conserved in IL-33
orthologues and we found no evidence for IL-33 processing in vivo
[3]. Two mechanisms have previously been shown to be involved
in the release of chromatin-associated cytokine HMGB1, secretion
by activated macrophages after hyperacetylation of lysine residues
[22] or passive release by necrotic cells during cell damage or
tissue injury [19]. Significant expression of IL-33 mRNA in
human hematopoietic cells was not detected in previous qPCR
studies [2], and accordingly, in the present work, we did not
observe expression of IL-33 protein in CD3
+ lymphocytes, CD68
+
Figure 5. IL-33 is abundantly expressed in the nucleus of
endothelial cells in human tumor tissues. Expression of IL-33 in
the indicated human tumor tissues was analyzed using immunofluo-
rescence staining. Double staining was performed with IL-33 mAb
Nessy-1 (red) and anti-CD31 or anti-vWF polyclonal antibodies (green).
DNA was counter-stained with DAPI. Magnification bars: A,B,G,H 50 mm;
C,D,E,F 20 mm.
doi:10.1371/journal.pone.0003331.g005
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+ dendritic cells. Therefore, active
secretion by macrophages or dendritic cells is unlikely to be a
major mechanism of IL-33 release in vivo. An alternative and more
likely possibility is that IL-33 may be released from dead or dying
cells during trauma or infection, and may function, similarly to
HMGB1, as an endogenous ‘danger’ signal or ‘alarmin’ [23], to
alert the immune system of cell or tissue damage. In this respect,
mast cells, that constitute a major cellular target of IL-33 [2,5–7]
and are strategically positioned closed to vessel walls and epithelial
surfaces exposed to the environment (including the skin and
gastrointestinal tract) [28], could play an important role in the
response to the IL-33 ‘alarmin’ signal released by damaged
endothelial or epithelial cells. Mast cells are widely recognized for
their roles as effector cells in allergic disorders, but are also
important as initiators and effectors of innate immunity [28], and
IL-33 may turn out to be a critical activator of mast cells during
innate immune response to pathogens. IL-33 could act alone or in
concert with other mediators, such as thymic stromal lympho-
poietin (TSLP), which is also expressed by inflamed skin and
tonsillar crypt epithelium, and can be released by epithelial cells in
response to trauma or infection [5,29,30].
The possibility that IL-33 may play important roles in the
response to trauma and infection is further supported by the
observation that increased serum levels of a soluble form of the IL-
33 receptor ST2 have been associated with numerous human
diseases, including sepsis and trauma [31], acute myocardial
infarction [32], chronic heart failure [33], idiopathic pulmonary
fibrosis [34], asthma and allergic airway inflammation [35],
rheumatoid arthritis and systemic lupus erythematosus [36]. The
increase in serum levels of soluble ST2 likely results from the
activation (or recruitment) by IL-33 of target cells co-expressing
the membrane and secreted forms of the ST2 receptor, thus
providing evidence for IL-33 release (or activation) in all these
diseases. Our observations that demonstrate constitutive expres-
sion of IL-33 in normal human tissues are therefore important,
because they suggest IL-33 can potentially be released in any tissue
after injury (after endothelial or epithelial cell damage), and this
could explain why the IL-33/ST2 signaling system appears to be
involved in numerous human diseases affecting many different
organs.
Although IL-33 was generally not detected in fibroblasts from
normal human tissues, it was found to be constitutively expressed
in the nucleus of T-zone FRCs of lymphoid tissues. FRCs play
critical roles in lymph node organization and function by
modulating lymphocyte survival and migration within T-cell areas
[25,37]. FRCs have been found to be major sources of cytokines
and chemokines, such as the pro-survival factor IL-7 and the
CCR7 ligands CCL19 and CCL21 [37,38]. Our observations
indicate that T-zone FRCs also constitute a major cellular source
of IL-33 in secondary lymphoid organs. An intriguing possibility is
that IL-33, which exhibits chemotactic properties for Th2
lymphocytes [11], may modulate migration of Th2 lymphocytes
through HEV walls and FRC networks within T-cell areas in
lymph nodes during infection. T-zone FRCs have been shown to
exhibit myofibroblastic features, including the expression of a-
SMA that is associated with increased generation of contractile
forces [25,37,39,40]. The expression of IL-33 in SMA
+ FRCs may
therefore be linked to their contractile myofibroblastic phenotype.
Interestingly, IL-33 expression has also been shown to be
biomechanically-induced in rat cardiac fibroblasts during their
Figure 6. IL-33 is constitutively expressed in the nucleus of epithelial cells in tissues exposed to the environment. A–C: Skin
keratinocytes; D–F: Epithelial cells of the mucosal surface in the stomach; G–H: Epithelial cells of the gastric glands in the stomach; I: Epithelial cells of
the salivary glands. Immunohistochemical and immunofluorescence staining were performed with IL-33 mAb Nessy-1. For immunofluorescence, IL-33
expression was detected in red and DNA was counter-stained with DAPI (blue). Magnification bars: 70 mm.
doi:10.1371/journal.pone.0003331.g006
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blasts with myofibroblast characteristics suggests involvement of
IL-33 in normal and pathological wound healing, tissue fibrosis
and connective-tissue remodeling after injury, processes in which
myofibroblasts play critical roles [39,40].
Surprisingly, we did not find expression of IL-33 in vascular
smooth muscle cells from arterial blood vessels in normal human
tissues, although expression in these cells has previously been
reported using cultured cells in vitro [2]. Expression in cultured cells
could result from a contractile phenotype biomechanically induced
by culture of the cells on plastic. In support of this possibility, the
mRNA encoding the canine orthologue of IL-33 (DVS27), has
been found to be strongly upregulated during cerebral vasospasm,
a complex pathological process characterized by prolonged
contraction of arterial smooth muscle cells [41]. The apparent
association of IL-33 expression with contractile forces in both
smooth muscle cells and myofibroblasts [4,41], supports an
important role of IL-33 in the response to tissue injury, in
addition to its roles in the response to infection. For instance, the
IL-33/ST2 signaling system may be particularly important in the
heart response to stress and injury during cardiovascular diseases
[4,32,33,42].
In summary, the results presented in this manuscript are
important because they demonstrate constitutive expression of IL-
33 in the nucleus of endothelial cells and epithelial cells in normal
human tissues. Based on this tissue distribution, we speculate that
IL-33 may function as an endogenous ‘alarmin’, similarly to
chromatin-associated cytokine HMGB1, to alert the immune
system of tissue injury or infection. Future studies should aim at
determining the mechanisms of IL-33 release and presentation to
the IL-33 signaling receptor complex, and defining the precise
roles of IL-33 in human health and disease, including its functions
at the level of chromatin in the nucleus of endothelial cells in vivo.
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